Brokerages Set Sight Sciences, Inc. (NASDAQ:SGHT) Target Price at $3.93

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have earned an average rating of "Hold" from the seven analysts that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.93.

Several research analysts have weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Citigroup reissued a "neutral" rating and set a $3.60 target price (up from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Piper Sandler reaffirmed a "neutral" rating and issued a $4.00 price objective (up from $3.50) on shares of Sight Sciences in a research note on Wednesday, June 18th. Wall Street Zen downgraded Sight Sciences from a "hold" rating to a "sell" rating in a research report on Friday. Finally, Lake Street Capital raised their price objective on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research report on Friday, May 9th.

Insider Buying and Selling at Sight Sciences

In other news, insider Jeremy B. Hayden sold 9,160 shares of the stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.17, for a total transaction of $38,197.20. Following the sale, the insider directly owned 266,321 shares of the company's stock, valued at $1,110,558.57. This represents a 3.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paul Badawi sold 23,637 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $4.15, for a total transaction of $98,093.55. Following the completion of the transaction, the chief executive officer directly owned 5,986,943 shares in the company, valued at $24,845,813.45. This represents a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,365 shares of company stock worth $180,017. 28.90% of the stock is owned by insiders.

Institutional Trading of Sight Sciences

Several institutional investors have recently added to or reduced their stakes in SGHT. KCK LTD. purchased a new position in Sight Sciences during the second quarter worth about $18,069,000. Long Focus Capital Management LLC raised its position in shares of Sight Sciences by 158.8% in the 4th quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock worth $8,149,000 after buying an additional 1,373,535 shares during the period. B Group Inc. purchased a new position in shares of Sight Sciences in the 4th quarter valued at $2,291,000. Prosight Management LP increased its position in shares of Sight Sciences by 71.1% in the 4th quarter. Prosight Management LP now owns 908,847 shares of the company's stock worth $3,308,000 after purchasing an additional 377,625 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Sight Sciences by 654.3% in the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.

Sight Sciences Stock Up 4.1%

SGHT traded up $0.14 during trading on Friday, hitting $3.57. The company had a trading volume of 79,169 shares, compared to its average volume of 206,545. The business has a 50-day moving average of $3.80 and a 200-day moving average of $3.13. The company has a current ratio of 10.47, a quick ratio of 9.99 and a debt-to-equity ratio of 0.51. Sight Sciences has a 1-year low of $2.03 and a 1-year high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The company had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. On average, equities analysts anticipate that Sight Sciences will post -0.99 EPS for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.